Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer
Status:
Terminated
Trial end date:
2019-11-04
Target enrollment:
Participant gender:
Summary
This study will evaluate NanoPac® administered intraperitoneally (IP) immediately
post-cytoreductive surgery, followed by standard of care (SOC) intravenous (IV) chemotherapy,
in women with ovarian cancer. The study will compare IP NanoPac® (plus IV chemotherapy) with
SOC IV chemotherapy alone.